Lupin is currently trading at Rs 442.00, up by 2.15 points or 0.49% from its previous closing of Rs 439.85 on the BSE.
The scrip opened at Rs 440.00 and has touched a high and low of Rs 445.00 and Rs 440.00 respectively. So far 17588 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 2 has touched a 52 week high of Rs 495.00 on 06-Jan-2011 and a 52 week low of Rs 363.00 on 25-Feb-2011.
Last one week high and low of the scrip stood at Rs 445.25 and Rs 419.10 respectively. The current market cap of the company is Rs 19692.76 crore.
The promoters holding in the company stood at 46.94% while Institutions and Non-Institutions held 43.33% and 9.72% respectively.
Pharma Major Lupin has received US Food and Drug Administration (USFDA) nod to market generic Fenofibrate Tablets, a cholesterol lowering drug, in the American market. The company has got the approval to sell 48 mg and 145 mg of generic Fenofibrate tablets in the American market. However, the company did not revealed the possible launch date of the product.
Earlier Abbott, the innovator of the drug, had filed patent litigations against seven firms, out of which five including those against Lupin and Teva have been settled. Abbott sells the drug under Tricor brand.
Further, Lupin could launch its generic version as early as July next year.
Earlier in December, Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) received tentative approval for its Duloxetine Hydrochloride Delayed-release (HCL DR) Capsules 20 mg, 30 mg and 60 mg from the United States Food and Drugs Administration (USFDA) for the company’s Abbreviated New Drug Application (ANDA) to market a generic version of Eli Lily & Company’s Cymbalta Delayed-release Capsules.
Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
